


SECTION 1: PRODUCT IDENTIFICATION

PRODUCT NAME	NALTREXONE HYDROCHLORIDE, USP (Anhydrous)
PRODUCT CODE	3296
SUPPLIER	MEDISCA Inc. Tel.: 1.800.932.1039 Fax.: 1.855.850.5855 626 Tom Miller Road, Plattsburgh, NY, 12901 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020
EMERGENCY PHONE	CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 National Chemical Emergency Centre 44(0)1235239670
RECOMMENDED USES	Pharmaceutical Manufacturing
RESTRICTIONS ON USE	Not applicable

SECTION 2: HAZARDS IDENTIFICATION

GHS CLASSIFICATION	Acute Toxicity - Oral (Category 4) Specific Target Organ Toxicity - Repeated Exposure (Category 2) - (Liver) Acute Aquatic Toxicity (Category 2)
PICTOGRAM	
SIGNAL WORD	Warning
HAZARD STATEMENT(S)	Harmful if swallowed. May cause respiratory tract irritation. May cause damage to organs (liver) through prolonged or repeated exposure. Suspected of damaging fertility or the unborn child Exposure may produce an allergic reaction. Toxic to aquatic life.
ADVERSE PHYSIOCHEMICAL, HUMAN HEALTH AND ENVIRONMENTAL EFFECTS	Not Applicable.
PRECAUTIONARY STATEMENT(S)	Prevention Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. Obtain, read and follow all special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves, protective clothing, eye and face protection and hearing protection. Do not breathe dust/fume/gas/mist/ vapors/spray. Avoid release to the environment.

Response IF SWALLOWED: Immediately call a poison center. Get medical help. Rinse mouth.
IF EXPOSED OR CONCERNED: Get medical advice.
Get medical help if you feel unwell.

Storage Store locked up.

Disposal Dispose of contents and/or container in accordance with local regulations.

HMIS CLASSIFICATION

Health Hazard

1

Flammability

0

Reactivity

0

Personal Protection

E

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

CHEMICAL NAME

Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, hydrochloride, (5a)- dihydrate

BOTANICAL NAME

Not applicable

SYNONYM

Not applicable

CHEMICAL FORMULA

C₂₀H₂₃NO₄.HCl

CHEMICAL FAMILY

Oxymorphone

CAS NUMBER

16676-29-2

ALTERNATE CAS NUMBER

Not applicable

MOLECULAR WEIGHT

377.86

COMPOSITION

CHEMICAL NAME	CAS NUMBER	EC NUMBER	% BY WEIGHT
NALTREXONE HYDROCHLORIDE (Anhydrous)	16676-29-2	240-723-0	100

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

NOTES

Opioid receptor antagonist

SECTION 4: FIRST-AID MEASURES

IN CASE OF EYE CONTACT

Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek medical aid.

IN CASE OF SKIN CONTACT

Wash with soap & water for 15 minutes. If irritation persists seek medical aid.

IF SWALLOWED

Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.

IF INHALED

Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a physician

MEDICAL ATTENTION AND SPECIAL TREATMENT

Get emergency medical help.

SYMPTOMS CAUSED BY EXPOSURE

Not expected to present a significant hazard under anticipated conditions of normal use.

SECTION 5: FIREFIGHTING MEASURES

SPECIFIC HAZARDS ARISING FROM THE CHEMICAL

Combustion products CO, CO₂, NO_x, hydrogen chloride, phosgene, other pyrolysis products and typical burning organic material.

FLAMMABLE PROPERTIES

May be combustible at high temperature

HAZARDOUS COMBUSTION PRODUCTS

Under fire conditions, hazardous fumes will be present.

**SUITABLE & UNSUITABLE
EXTINGUISHING MEDIA**

Small fire: dry chemical, CO₂ or water spray. **Large fire:** dry chemical, CO₂, alcohol resistant foam or water spray. Do not get water inside containers.

**PROTECTIVE EQUIPMENT AND
PRECAUTIONS FOR FIREFIGHTERS**

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

SECTION 6: ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS

Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

**METHODS & MATERIAL FOR
CONTAINMENT**

On land, sweep or shovel into suitable containers. Minimize generation of dust.

CLEANUP PROCEDURE

Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean the affected area. Do not flush into sewerage system or to drains.

REFERENCE TO OTHER SECTIONS

See Section 7 for information on safe handling. See Section 8 for information on personal protection equipment. See Section 13 for disposal information.

SECTION 7: HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING

Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

CONDITIONS FOR SAFE STORAGE

Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

STORAGE CONDITIONS

Store in original container, tightly sealed, protected from direct sunlight and moisture.

Short term excursions, temperature excursions as experienced during shipping and warehousing, up to 40 °C are acceptable.

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

Chemical Name: NALTREXONE HYDROCHLORIDE (Anhydrous) **CAS #:** 16676-29-2

	Country	Limit value-8 hours		Limit value-Short Term		IDLH	REL	Advisory	Notes
		ppm	mg/m ³	ppm	mg/m ³				
OSHA	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
ACGIH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
NIOSH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
WEEL	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSIS	Australia	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

HSE	UK	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
GESTIS	Add Country	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

N/L = Not listed ; N/A = Not Available

PELs are 8-hour TWAs = Limit value - Eight hours

Ceiling or Short-Term TWA = STEL = Limit value - Short term

EXPOSURE GUIDELINES

Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable fraction: 5 mg/m³

PERSONAL PROTECTIVE EQUIPMENT

Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. **Skin:** Wear appropriate gloves to prevent skin exposure. **Clothing:** Wear appropriate protective clothing to minimize contact with skin. **Respirators:** Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. **Thermal Hazards:** For products representing a thermal hazard, appropriate Personal Protective Equipment should be used.

SPECIFIC ENGINEERING CONTROLS

Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

BIOLOGICAL MONITORING

Not available

CONTROL BANDING

Not available

NOTES

Route of exposure (Oral): Permitted daily Exposure (µg/day): 150
 Manufacturer OEL: TWA: 50 µg/m³ (8 hrs)
 Manufacturer STEL: TWA: 500 µg/m³ (15 minutes)

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES
PHYSICAL STATE

Solid

DESCRIPTION

White to almost white powder. Very hygroscopic.

SOLUBILITY

Very soluble in water; slightly soluble in alcohol; practically insoluble in dichloromethane and methylene chloride.

ODOR

Almost odorless or intrinsic odor

FLAMMABILITY

May be combustible at high temperature

AUTO-IGNITION TEMPERATURE

Not available

BOILING POINT

Not available

DECOMPOSITION TEMPERATURE

270 °C, 518 °F

EVAPORATION RATE

Not available

EXPLOSIVE LIMIT

Not available

FLASH POINT

Not available

log P (OCTANOL-WATER)

1.84

LOWER FLAMMABLE/EXPLOSIVE LIMIT(S)

Not available

MELTING/FREEZING POINT

210 °C, 410 °F

PARTICLE CHARACTERISTICS

Not available

OXIDIZING PROPERTY

Not available

pH

4.5 - 6.0 (1%)

RELATIVE DENSITY (WATER = 1)

Not available

SPECIFIC GRAVITY

Not available

UPPER FLAMMABLE/EXPLOSIVE LIMIT(S)

Not available

VAPOR DENSITY (AIR = 1)

Not available

VAPOR PRESSURE

Not available

VISCOSITY

Not available

The physical data presented above are typical values and should not be construed as a specification.

SECTION 10: STABILITY AND REACTIVITY

REACTIVITY	Not established
CHEMICAL STABILITY	Stable under recommended storage conditions
INCOMPATIBLE MATERIALS	Strong oxidizing agents. Bases.
HAZARDOUS DECOMPOSITION PRODUCTS	Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and other gases may occur
HAZARDOUS POLYMERIZATION	Will not occur
POSSIBILITY OF HAZARDOUS REACTION	Not established
CONDITIONS TO AVOID	Moisture, sunlight and extreme temperatures. Hygroscopic - Avoid exposure to moisture.

SECTION 11: TOXICOLOGICAL INFORMATION

ACUTE TOXICITY	Oral: Rat: LD50: (mg/kg): 1450 Dermal: Rabbit: LD50: (mg/kg): Not available Inhalation: Rat: LC50: (mg/L/4hr): Not available
SKIN CORROSION/IRRITATION	Due to lack of data the classification is not possible. Dust or powder may irritate the skin. Prolonged skin contact may cause temporary irritation.
SERIOUS EYE DAMAGE/EYE IRRITATION	Due to lack of data the classification is not possible. Dust may irritate the eyes. Direct contact with eyes may cause temporary irritation.
RESPIRATORY SENSITIZATION	Due to lack of data the classification is not possible. Dusts may irritate the respiratory tract. Prolonged inhalation may be harmful. Possible hypersensitization.
SKIN SENSITIZATION	Based on available data, the classification criteria are not met. May cause an allergic skin reaction. In pharmacological use, rare cases of hypersensitivity are reported. Suspected skin sensitizer: CAESAR skin sensitisation model in VEGA (Q)SAR platform predicts that the chemical is Sensitizer (moderate reliability).
GERM CELL MUTAGENICITY	Due to lack of data the classification is not possible. Suspected of causing genetic defects. Germ cell mutagenicity- Assessment: In vitro tests showed mutagenic effects. In pharmacological use, barbiturates are associated with congenital heart malformations, facial clefts, and other malformations.
CARCINOGENICITY	OSHA NALTREXONE HYDROCHLORIDE (Anhydrous) is not listed. NTP NALTREXONE HYDROCHLORIDE (Anhydrous) is not listed. IARC NALTREXONE HYDROCHLORIDE (Anhydrous) is not evaluated. California Proposition 65 This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.
ADDITIONAL CARCINOGENICITY INFORMATION	Based on available data, the classification criteria are not met. In two-year studies in rats given naltrexone, there were small increases in the numbers of testicular mesotheliomas in males and tumors of vascular origin in both sexes. Only the incidence of vascular tumors in females (4%) exceeded the maximum (2%) reported in historical control groups. No evidence of carcinogenicity was observed in several other two-year studies in mice or rats receiving naltrexone.

REPRODUCTIVE TOXICITY

Based on available data, the classification criteria are not met.
 Suspected of damaging fertility or the unborn child.
 Reduced weight in neonates.
 Teratogenicity - Assessment: :Potential embryo-foetal toxicity and teratogenicity.
 Suspected toxic for reproduction: CAESAR developmental toxicity model in VEGA (Q)SAR platform predicts that the chemical is Toxicant (good reliability)

SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE

Based on available data, the classification criteria are not met.
 May cause drowsiness and dizziness.
 Inhalation of dust can irritate the respiratory tract.

SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE

Repeated ingestion may cause liver damage. Repeated exposure may cause hepatitis and liver disease.

ASPIRATION HAZARDS

Due to lack of data the classification is not possible.

SIGNS AND SYMPTOMS OF EXPOSURE
ROUTES OF EXPOSURE:

Oral, Dermal, Inhalation, Eye contact

EARLY ONSET SYMPTOMS RELATED TO EXPOSURE:

Not available

DELAYED HEALTH EFFECT FROM EXPOSURE:

Not available

Symptoms related to the physical, chemical, and toxicological characteristics:

Ingestion may provoke the following symptoms: constriction of pupils, abdominal pain, vomiting, headache, and liver disorders. Dusts may irritate the respiratory tract, skin and eyes. May cause an allergic skin reaction. Dermatitis. Rash.

May cause drowsiness and dizziness. Nausea.

May cause central nervous system disorder (e.g., narcosis involving a loss of coordination, weakness, fatigue, mental confusion and blurred vision) and/or damage.

Information in drug literature indicates this substance has been shown to have embryocidal effects in experimental animals at large doses. May produce acute withdrawal symptoms in individuals physically dependent on opioids.

POTENTIAL HEALTH EFFECTS

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion Harmful if swallowed.

Skin May be harmful if absorbed through skin. May cause skin irritation.

Eyes Causes serious eye irritation.

SECTION 12: ECOLOGICAL INFORMATION
ECOTOXICITY

EC50: 48 Hr: Crustacea: Daphnia: (mg/L): 2.23*

LC50: 96 Hr: Fish: (mg/L): 23.18*

EC50: 96 Hr: Algae: Green Algae: (mg/L): 9.28*

PERSISTENCE AND DEGRADABILITY

Suspected persistent in the environment: Ready biodegradability model (IRFMN) in VEGA (Q)SAR platform predicts that the chemical is NON Readily Biodegradable (moderate reliability);The Danish QSAR database contains information indicating that the substance is predicted as non readily biodegradable

BIOACCUMULATIVE POTENTIAL

Log Pow = 1.84

MOBILITY IN SOIL

Very soluble in water. (> 100 mg/L)

OTHER ADVERSE EFFECTS

Not available

This product is not intended to be released into the environment

NOTES

*Danish QSAR database

SECTION 13: DISPOSAL CONSIDERATIONS

DISPOSAL METHODS

Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.

SECTION 14: TRANSPORT INFORMATION
UN PROPER SHIPPING NAME Not dangerous good

UN NUMBER Not applicable

CLASS Not applicable

PACKING GROUP Not applicable

AUSTRALIA
HAZCHEM Not applicable

EU
TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE IBC CODE Not Listed

ENVIRONMENTAL HAZARDS Not available

SPECIAL SHIPPING INFORMATION Not applicable

SECTION 15: REGULATORY INFORMATION
UNITED STATES REGULATIONS

Chemical Name & CAS	CERCLA 40 CFR Part 302.4	SARA (Title III) 40 CFR Part 372.65	EPA 40 CFR Part 355		Pennsylvania	Right-to-know		California Prop 65
			Appendix A	Appendix B		New Jersey	Massachusetts	
NALTREXONE HYDROCHLORIDE (Anhydrous) 16676-29-2	N/L	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

AUSTRALIAN REGULATIONS

Chemical Name & CAS	Poisons and Therapeutic Goods	Therapeutic Goods Act	Code of Practices - Illicit Drug Precursors	Poisons Standard	Work Health and Safety Regulations	Inventory of Industrial Chemicals
NALTREXONE HYDROCHLORIDE (Anhydrous) 16676-29-2	N/L	Listed as Schedule 4*	N/L	Listed*	N/L	N/L

N/L = Not Listed

EU REGULATIONS

Chemical Name & CAS	REACH ANNEX XVII	REACH ANNEX XIV	EC 1005/2009	EC 850/2004	EC 1107/2009	PIC - Prior Informed Consent Regulation	EC 2012/18
NALTREXONE HYDROCHLORIDE (Anhydrous) 16676-29-2	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

Any EU regulation not listed above is not applicable to this product.

SUBJECT TO INTERNATIONAL
AGREEMENT

Not applicable

NOTES

*Listed as Naltrexone

SECTION 16: OTHER INFORMATION

REFERENCES

Available upon request

ABBREVIATIONS AND ACRONYMS

ACGIH - American Conference of Governmental Industrial Hygienists; **AIHA WEEL** – American Industrial Hygiene Association Workplace Environment Exposure Levels; **CAESAR** – Computer Assisted Evaluation of industrial chemical Substances According to Regulations; **CAS** – Chemical Abstract Service; **CERCLA** – Comprehensive Environmental Response, Compensation, and Liability Act; **EC50** – Effective Concentration, 50%; **EPA** – Environmental Protection Agency; **GHS** – Global Harmonized System; **HMIS** – Hazardous Materials Information System; **HSE** – Health and Safety Executive; **HSIS** – Hazardous Substances Information System; **IARC** – International Agency for Research on Cancer; **IDLH** - Immediately Dangerous to Life or Health; **IRFMN** – Ready Biodegradability Model; **ISS** – Istituto Superiore Sanità; **LC50** – Lethal Concentration, 50%; **LD50** – Lethal Dose, 50%; **MSHA** - Mine Safety and Health Administration; **NIOSH** – National Institute for Occupational Safety and Health; **NTP** – National Toxicology Program; **OSHA PEL** – Occupational Safety & Health Administration Permissible Exposure Limits; **QSAR** – Quantitative Structure-activity relationship; **REL** - Recommended Exposure Limit; **SARA** – Superfund Amendments and Reauthorization Act; **STEL** – Short Term Exposure Limit; **TLV** – Threshold Limit Value; **TWA** – Time Weighted Average; **WHMIS** – Workplace Hazardous Materials Information System

LAST REVISION

04/2025

SUPERSEDES

07/2024

For a list of changes to the SDS since the last version, please communicate with MEDISCA at www.medisca.com

DISCLAIMER

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.

SUPPLEMENTARY INFORMATION

For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet.